Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial

TRA 2(o)P-TIMI 50 Investigators, Graeme John Hankey

Research output: Contribution to journalArticle

159 Citations (Scopus)

Fingerprint Dive into the research topics of 'Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences